Travere Therapeutics announces FDA acceptance and priority review of new drug application for sparsentan for the treatment of IgA nephropathy

Travere Therapeutics

16 May 2022 - PDUFA target action date of 17 November 2022.

Travere Therapeutics today announced the U.S. FDA has accepted and granted priority review of its new drug application under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy.

Read Travere Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Priority review , Dossier